GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Common Stock

Aurinia Pharmaceuticals (FRA:IKAP) Common Stock : €1,087.2 Mil (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Common Stock?

Aurinia Pharmaceuticals's quarterly common stock increased from Mar. 2024 (€1,111.3 Mil) to Jun. 2024 (€1,120.0 Mil) but then declined from Jun. 2024 (€1,120.0 Mil) to Sep. 2024 (€1,087.2 Mil).

Aurinia Pharmaceuticals's annual common stock increased from Dec. 2021 (€1,041.7 Mil) to Dec. 2022 (€1,118.9 Mil) but then declined from Dec. 2022 (€1,118.9 Mil) to Dec. 2023 (€1,100.6 Mil).


Aurinia Pharmaceuticals Common Stock Historical Data

The historical data trend for Aurinia Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Common Stock Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 671.84 776.24 1,041.69 1,118.93 1,100.60

Aurinia Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,123.05 1,100.60 1,111.34 1,119.96 1,087.16

Aurinia Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Aurinia Pharmaceuticals Business Description

Traded in Other Exchanges
Address
14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals Headlines

No Headlines